4.7 Review

The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia

Journal

LEUKEMIA
Volume 29, Issue 8, Pages 1623-1631

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2015.113

Keywords

-

Funding

  1. Marie Curie International Incoming Fellowship
  2. European Research Council
  3. Leukaemia and Lymphoma Research
  4. Cancer Research UK
  5. Kay Kendall Leukaemia Fund
  6. Medical Research Council career development award [MR/J008060/1]
  7. CR-UK [C27943/A12788]
  8. Cancer Research UK [16857, 12788] Funding Source: researchfish
  9. Medical Research Council [MR/J008060/1] Funding Source: researchfish
  10. The Francis Crick Institute [10057] Funding Source: researchfish
  11. MRC [MR/J008060/1] Funding Source: UKRI

Ask authors/readers for more resources

The B-cell receptor (BCR) and its immature form, the precursor-BCR (pre-BCR), have a central role in the control of B-cell development, which is dependent on a sequence of cell-fate decisions at specific antigen-independent checkpoints. Pre-BCR expression provides the first checkpoint, which controls differentiation of pre-B to immature B-cells in normal haemopoiesis. Pre-BCR signalling regulates and co-ordinates diverse processes within the pre-B cell, including clonal selection, proliferation and subsequent maturation. In B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), B-cell development is arrested at this checkpoint. Moreover, malignant blasts avoid clonal extinction by hijacking pre-BCR signalling in favour of the development of BCP-ALL. Here, we discuss three mechanisms that occur in different subtypes of BCP-ALL: (i) blocking pre-BCR expression; (ii) activating pre-BCR-mediated pro-survival and pro-proliferative signalling, while inhibiting cell cycle arrest and maturation; and (iii) bypassing the pre-BCR checkpoint and activating pro-survival signalling through pre-BCR independent alternative mechanisms. A complete understanding of the BCP-ALL-specific signalling networks will highlight their application in BCP-ALL therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia

Yuzhe Shi, Melanie C. Beckett, Helen J. Blair, Ricky Tirtakusuma, Sirintra Nakjang, Amir Enshaei, Christina Halsey, Josef Vormoor, Olaf Heidenreich, Anja Krippner-Heidenreich, Frederik W. van Delft

Summary: The study identified the critical role of LCK in T-cell acute lymphoblastic leukemia (T-ALL) cell proliferation, with combination therapy of LCK inhibition with dasatinib (DAS) leading to cell death, which was enhanced by dexamethasone (DEX). These findings provide a strategy to improve the efficacy of current chemotherapy and overcome glucocorticoid resistance in high-risk T-ALL patients.

HAEMATOLOGICA (2021)

Article Oncology

H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells

Laura Godfrey, Nicholas T. Crump, Sorcha O'Byrne, I-Jun Lau, Siobhan Rice, Joe R. Harman, Thomas Jackson, Natalina Elliott, Gemma Buck, Christopher Connor, Ross Thorne, David J. H. F. Knapp, Olaf Heidenreich, Paresh Vyas, Pablo Menendez, Sarah Inglott, Philip Ancliff, Huimin Geng, Irene Roberts, Anindita Roy, Thomas A. Milne

Summary: MLL gene rearrangements are a common cause of aggressive and incurable acute lymphoblastic leukemias in infants and children, with the most common MLLr producing an MLL-AF4 fusion protein that promotes leukemogenesis by activating key target genes. The aberrant expression of PROM1/CD133 is essential for leukemic cell growth, mediated by direct binding of MLL-AF4 and controlled by an intragenic H3K79me2/3 enhancer element. The dual locus regulation between PROM1 and the nearby gene TAPT1 is reflected in a strong correlation of expression in leukemia.

LEUKEMIA (2021)

Article Multidisciplinary Sciences

Permissive selection followed by affinity-based proliferation of GC light zone B cells dictates cell fate and ensures clonal breadth

Rinako Nakagawa, Amparo Toboso-Navasa, Marta Schips, George Young, Leena Bhaw-Rosun, Miriam Llorian-Sopena, Probir Chakravarty, Abdul Karim Sesay, George Kassiotis, Michael Meyer-Hermann, Dinis Pedro Calado

Summary: Affinity maturation in germinal centers depends on efficient positive selection of B cells in the light zone. Different subpopulations of cMyc(+) GC B cells are identified and characterized, with higher-affinity cells diverging towards plasmablasts and lower-affinity cells towards memory B cell precursors. This dynamic process of positive selection leads to the generation of three distinct B cell fates, ensuring clonal diversity for broad protection.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Medicine, Research & Experimental

A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability

Elizabeth A. Kuczynski, Giulia Morlino, Alison Peter, Anna M. L. Coenen-Stass, Jennifer Moss, Neha Wali, Oona Delpuech, Avinash Reddy, Anisha Solanki, Charles Sinclair, Dinis P. Calado, Larissa S. Carnevalli

Summary: This study established a novel mouse model of PTCL by transplanting lymphoma cells into immune-competent mice, which exhibited similar B-cell activation and lymphomagenesis as observed in human PTCL. Molecular profiling identified specific gene expressions and mutations related to high-risk PTCL subtype. Targeting the DNA damage response pathway led to prolonged treatment responses in vivo, suggesting the potential of DDR inhibition as an effective therapy for PTCL.

EMBO MOLECULAR MEDICINE (2022)

Review Oncology

Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma

Erica Brivio, Andre Baruchel, Auke Beishuizen, Jean-Pierre Bourquin, Patrick A. Brown, Todd Cooper, Lia Gore, E. Anders Kolb, Franco Locatelli, Shannon L. Maude, Francis J. Mussai, Britta Vormoor-Burger, Josef Vormoor, Arend von Stackelberg, C. Michel Zwaan

Summary: Despite improvements in treating newly diagnosed leukaemia and lymphoma in children, refractory or relapsed cases remain difficult to manage. Novel agents that offer less toxicity while maintaining efficacy are being explored. However, drug development for paediatric cancers lags behind adult therapeutic options.

EUROPEAN JOURNAL OF CANCER (2022)

Article Medicine, General & Internal

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial

Tobias Menne, Daniel Slade, Joshua Savage, Sarah Johnson, Julie Irving, Pamela Kearns, Ruth Plummer, Geoff Shenton, Gareth J. Veal, Britta Vormoor, Josef Vormoor, Lucinda Billingham

Summary: The study aims to evaluate the combination of selumetinib and dexamethasone in adult and paediatric patients with relapsed/refractory RAS pathway mutant ALL. The research will be conducted in multiple countries and results will be disseminated through national and international conferences and peer-reviewed publications.

BMJ OPEN (2022)

Review Biochemistry & Molecular Biology

Elucidating miRNA Function in Cancer Biology via the Molecular Genetics' Toolbox

Adam Azlan, Yaashini Rajasegaran, Khor Kang Zi, Aliaa Arina Rosli, Mot Yee Yik, Narazah Mohd Yusoff, Olaf Heidenreich, Emmanuel Jairaj Moses

Summary: This review highlights the dysregulation mechanisms of miRNAs in cancer and discusses the advantages and disadvantages of various molecular genetics tools for studying miRNA function, focusing on CRISPR/Cas systems. It provides general workflows and practical considerations to help researchers choose the appropriate tools for their experiments.

BIOMEDICINES (2022)

Article Biochemistry & Molecular Biology

High-resolution simulations of chromatin folding at genomic rearrangements in malignant B cells provide mechanistic insights into proto-oncogene deregulation

Daniel Rico, Daniel Kent, Nefeli Karataraki, Aneta Mikulasova, Rolando Berlinguer-Palmini, Brian A. Walker, Biola M. Javierre, Lisa J. Russell, Chris A. Brackley

Summary: This study used a predictive model to predict chromatin conformation of the proto-oncogene CCND1 in both healthy and malignant B cells, and found that genomic rearrangements involving CCND1 can lead to chromatin remodeling and oncogene activation.

GENOME RESEARCH (2022)

Review Oncology

Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood

Isobelle Wall, Victoire Boulat, Aekta Shah, Kim R. M. Blenman, Yin Wu, Elena Alberts, Dinis Pedro Calado, Roberto Salgado, Anita Grigoriadis

Summary: The tumor microenvironment (TME), lymph nodes (LNs), and peripheral blood form the interconnected immune sites in breast cancer. Understanding the dynamic interaction between these immune sites is crucial for improving anti-cancer responses and therapeutic outcomes in breast cancer patients.

CANCERS (2022)

Article Oncology

Novel Adaption of the SARC-F Score to Classify Pediatric Hemato-Oncology Patients with Functional Sarcopenia

Emma J. Verwaaijen, Patrick van der Torre, Josef Vormoor, Rob Pieters, Marta Fiocco, Annelies Hartman, Marry M. van den Heuvel-eibrink

Summary: Children treated for hemato-oncological diseases are at risk of muscle deterioration. The pediatric SARC-F (PED-SARC-F) is an accurate screening tool for identifying functional sarcopenia in these patients. A cut-off point of >= 5 has the highest specificity and reduces unnecessary assessments.

CANCERS (2023)

Article Oncology

Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia

Hasan Issa, Laura E. E. Swart, Milad Rasouli, Minoo Ashtiani, Sirintra Nakjang, Nidhi Jyotsana, Konstantin Schuschel, Michael Heuser, Helen Blair, Olaf Heidenreich

Summary: Hallmarks of AML include chromosomal rearrangements generating fusion genes, which are ideal therapeutic targets but difficult to treat conventionally. This study demonstrates the use of siRNA-loaded lipid nanoparticles to specifically target the leukaemic fusion gene RUNX1/ETO. Inhibition of RUNX1/ETO resulted in extended survival, reduced leukaemic proliferation, induced differentiation and impaired re-engraftment potential in vivo. These findings provide proof for targeting RUNX1/ETO and support further development of siRNA-LNPs for fusion gene-driven malignancies.

LEUKEMIA (2023)

Article Pharmacology & Pharmacy

Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles

Laura E. Swart, Marcel H. A. M. Fens, Anita van Oort, Piotr Waranecki, L. Daniel Mata Casimiro, David Tuk, Martijn Hendriksen, Luca van den Brink, Elizabeth Schweighart, Cor Seinen, Ryan Nelson, Anja Krippner-Heidenreich, Tom O'Toole, Raymond M. Schiffelers, Sander Kooijmans, Olaf Heidenreich

Summary: Lipid nanoparticles (LNPs) are rapidly evolving as promising delivery systems for oligonucleotides, including siRNAs. In this study, LNPs were specifically targeted to hematopoietic progenitor cells in the bone marrow using a modified tripeptide ligand. Functionalized LNPs showed improved uptake and delivery of siRNA in patient-derived leukemia cells, as well as increased accumulation and retention in the bone marrow. These findings suggest the potential of LNPs for targeted therapy in leukemia and other hematological disorders.

PHARMACEUTICS (2023)

Article Oncology

Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

Ruth Fluemann, Julia Hansen, Benedikt W. Pelzer, Pascal Nieper, Tim Lohmann, Ilmars Kisis, Tobias Riet, Viktoria Kohlhas, Phuong-Hien Nguyen, Martin Peifer, Nima Abedpour, Graziella Bosco, Roman K. Thomas, Moritz Kochanek, Jacqueline Knufer, Lorenz Jonigkeit, Filippo Beleggia, Alessandra Holzem, Reinhard Buttner, Philipp Lohneis, Jorn Meinel, Monika Ortmann, Thorsten Persigehl, Michael Hallek, Dinis Pedro Calado, Markus Chmielewski, Sebastian Klein, Joachim R. Goethert, Bjoern Chapuy, Branko Zevnik, F. Thomas Wunderlich, Bastian von Tresckow, Ron D. Jachimowicz, Ari M. Melnick, Hans Christian Reinhardt, Gero Knittel

Summary: Genomic profiling identified 5 subtypes of DLBCL, including the MCD/C5 cluster with MYD88, BCL2, PRDM1, and/or SPIB aberrations. Mouse models with B cell-specific Prdm1 or Spib aberrations were generated, showing molecular features of prememory and light-zone B cells. Combined BTK/BCL2 inhibition exhibited therapeutic activity in both mouse models and relapsed/refractory DLBCL patients.

BLOOD CANCER DISCOVERY (2023)

Meeting Abstract Pediatrics

Ex vivo and in vivo complex drug combination analysis for improved efficacy and specificity in high-risk childhood acute lymphoblastic leukaemia

E. Law, L. McKenzie, H. Blair, K. Szoltysek, M. Singh, S. Bomken, J. Lunec, J. Irving, J. Vormoor, O. Heidenreich

KLINISCHE PADIATRIE (2022)

Article Medicine, Research & Experimental

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma

Annalisa D'Avola, Nathalie Legrave, Mylene Tajan, Probir Chakravarty, Ryan L. Shearer, Hamish W. King, Katarina Kluckova, Eric C. Cheung, Andrew J. Clear, Arief S. Gunawan, Lingling Zhang, Louisa K. James, James MacRae, John G. Gribben, Dinis P. Calado, Karen H. Vousden, John C. Riches

Summary: The synthesis of serine from glucose plays a crucial role in cellular proliferation and is important in germinal center biology. This study shows that upregulation of serine synthesis pathway is a metabolic hallmark of B cell activation and the germinal center reaction, and inhibiting the key enzyme PHGDH leads to defective germinal formation and impaired antibody production. Furthermore, overexpression of enzymes involved in serine synthesis is characteristic of germinal center B cell-derived lymphomas, and inhibiting PHGDH can induce apoptosis in lymphoma cells, reducing disease progression.

JOURNAL OF CLINICAL INVESTIGATION (2022)

No Data Available